Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%
Stock Monitor: Aquinox Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free earnings report on Zoetis Inc. (NYSE: ZTS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZTS. The Company reported its fourth quarter fiscal 2017 and full fiscal year 2017 operating and financial results on February 14, 2018. The animal health Company outperformed top- and bottom-line expectations, and also provided guidance for the full year 2018. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP), which also belongs to the Healthcare sector as the Company Zoetis. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=AQXP
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zoetis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=ZTS
Earnings Highlights and Summary
Zoetis reported revenues of $1.46 billion for the fourth quarter of 2017, reflecting an increase of 14% compared to $1.28 billion in Q4 2016. On an operational basis, the Company's revenues, excluding the impact of foreign exchange, increased 13% on a y-o-y basis in the reported quarter. Zoetis' revenue numbers beat analysts' estimates of $1.40 billion.
For Q4 2017, Zoetis reported a net income of $81 million, or $0.16 per diluted share, compared to $154 million, or $0.31 per diluted share, in Q4 2016. The Company's reported quarter results included a net impact of $260 million for purchase accounting adjustments, acquisition-related costs, and certain significant items. Included in the $260 million, was a provisional net tax charge of $212 million related to recently-enacted tax legislation in the US.
For Q4 2017, Zoetis' adjusted net income was $341 million, or $0.69 per diluted share, compared to $232 million, or $0.47 per diluted share, in Q4 2016. The Company's earnings beat Wall Street's estimates of $0.66 per share.
For the full year FY17, Zoetis' revenues rose 9% to $5.31 billion compared to $4.89 billion in FY16. On an operational basis, the Company's revenues increased 8% on a y-o-y basis in FY17, excluding the impact of foreign exchange.
Zoetis' net income was $864 million, or $1.75 per diluted share, in FY17, an increase of 5% and 6%, respectively, compared to $821 million, or $1.65 per diluted share, in FY16. The Company's adjusted net income was $1.19 billion, or $2.40 per diluted share, in FY17 compared to $975 million, or $1.96 per diluted share, in FY16. The Company's adjusted net income FY17 excluded the net impact of $321 million for purchase accounting adjustments, acquisition-related costs, and certain significant items.
Segment Results
During Q4 2017, Zoetis' US segment's revenues jumped 13% to $712 million on a y-o-y basis. The segment's sales of companion animal products grew 15% in the reported quarter, driven by increased sales in its dermatology portfolio and several other new products, including Simparica® (sarolaner), an oral parasiticide.
In Q4 2017, the US segment's sales of livestock products grew 11% compared to the year ago same period, driven by a growth in its cattle and poultry portfolio. In the cattle portfolio, the growth was driven by increased sales of premium products, which were supported by favorable weather conditions that drove higher disease risk and incidence and more placements in feedlots, as well as the timing of promotional activities in the year ago same period. In the poultry portfolio, the growth was driven by increased sales of medicated feed additive products.
For Q4 2017, Zoetis' International segment's revenues rose 16% to $740 million on a y-o-y basis. The segment's sales of companion animal products grew 23% on a reported basis and 18% on an operational basis, resulting primarily from increased sales of Zoetis' dermatology portfolio and Simparica. Sales of livestock products grew 14% on a reported basis and 11% on an operational basis, driven by a balanced growth across the Company's portfolio.
Outlook
For the full fiscal year 2018, Zoetis is forecasting revenues to be in the range of $5.675 billion to $5.800 billion. The Company is estimating earnings per diluted share to be between $2.77 and $2.93, and adjusted earnings per diluted share to be in the band of $2.96 to $3.10.
Stock Performance Snapshot
March 16, 2018 - At Friday's closing bell, Zoetis' stock fell 1.78%, ending the trading session at $80.60.
Volume traded for the day: 2.60 million shares.
Stock performance in the last three-month – up 10.85%; previous six-month period – up 25.47%; past twelve-month period – up 49.81%; and year-to-date – up 11.88%
After last Friday's close, Zoetis' market cap was at $39.32 billion.
Price to Earnings (P/E) ratio was at 36.92.
The stock has a dividend yield of 0.62%.
The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
